The vagina is a key anatomical site in the pathogenesis of urinary tract infection (UTI) in women, serving as a potential reservoir for infecting bacteria and a site at which interventions may decrease the risk of UTI. The vaginal microbiota is a dynamic and often critical factor in this pathogenic interplay, because changes in the characteristics of the vaginal microbiota resulting in the loss of normally protective Lactobacillus spp. increase the risk of UTI. These alterations may result from the influence of estrogen deficiency, antimicrobial therapy, contraceptives, or other causes. Interventions to reduce adverse effects on the vaginal microbiota and/or to restore protective lactobacilli may reduce the risks of UTI. INTRODUCTION Urinary tract infections (UTIs) are a common clinical problem across the lifespan of women. Although UTIs are not systematically tracked, making estimates of U.S. incidence somewhat challenging, the most recent combined National Hospital Ambulatory Medical Care Survey and National Ambulatory Medical Care Survey data from 2009-2010 suggest that approximately 10 million outpatient visits for a diagnosis of UTI occur annually in the United States among both women and men (1). Women are disproportionately affected, with an estimated lifetime risk of UTI of 60% (2). In otherwise healthy, sexually active premenopausal women, these infections occur approximately every other year (3). As women age, UTIs become more common (2). A population-based study of community-onset UTI among nearly 31,000 residents of Calgary showed that the incidence of UTI among women demonstrates an initial peak in the twenties (30 per 1,000), decreases slightly during the later reproductive years, then steadily increases with every decade of life starting in late middle age, reaching a maximum of 125/1,000 at and above age 80 (4). Although the cost of treating UTI has not been recently estimated, the last published estimate in 2010 indicated that the annual U.S. domestic cost exceeded two billion dollars (5-7). Despite decades of studies defining the epidemiology, risk factors, and pathogenic mechanisms in UTIs, current evidence-based prevention strategies still rely upon the use of low-dose prophylactic antimicrobials as the cornerstone of prevention of recurrent UTIs in women of any age (8). For postmenopausal women, vaginal estrogen therapy may be considered, but this is often as an adjunctive to antimicrobial-based prophylaxis (8). Given